The three neurologst Dr. Sophie Lehnerer, Dr. Lea Gerischer und Dr. Maike Stein developed their digital solutions to support the care for patients suffering from the neuromuscular disease myastenis gravis.
A platform improving care for patients with myasthenia gravis!
Myasthenia gravis is a rare neurological autoimmune disease characterized by fluctuating muscle weakness that worsens with activity. About 17,000 people in Germany suffer from the disease. Many struggle to access appropriate care, especially if they need complex immunotherapies. The Spinoff RareLink now aims to address this gap with its MyaLink platform, which leverages remote monitoring to enable personalized therapy management. The young company is a spin-off of the Berlin Institute of Health (BIH), Charité – Universitätsmedizin Berlin and the telemedicine provider Qurasoft. It was supported by the BIH Digital Health Accelerator, the BIH CSP Program as well as Charité’s Neuroscience Clinical Research Center.
More information here